Pharmaceutical composition containing disrupted cell suspension of monilia albicans and euglobulin and method of treating animals infected with canine distemper virus of animals having neurological disorders by using the same

Abstract

Disclosed is a pharmaceutical composition which comprises a disrupted cell suspension of Monilia albicans and euglobulin as effective ingredients. The euglobulin is contained in the pharmaceutical composition in an amount of 10 to 250 mg per ml of the disrupted cell suspension M. albicans. Also, the present invention discloses a method of treating animals infected with canine distemper virus or animals with neurological disorders. The pharmaceutical composition has excellent therapeutic efficacy on animals with the canine distemper virus as well as animals with neurological disorders.

1 . A pharmaceutical composition comprising a disrupted cell suspension of  Monilia albicans  and euglobulin as effective ingredients.  
     
     
         2 . The pharmaceutical composition as set forth in  claim 1 , wherein the disrupted cell suspension of the  Monilia albicans  is prepared by culturing the  Monilia albicans  in a liquid culture medium, centrifuging the resulting culture fluid, recovering a supernatant and disrupting collected cells, and mixing the supernatant and a cell lysate after inactivation, wherein the culture fluid contains the Monilia albicans of about 1.2×10 9  cfu/ml.  
     
     
         3 . The pharmaceutical composition as set forth in  claim 1 , wherein the euglobulin is contained in the pharmaceutical composition in an amount of 10 mg to 250 mg per ml of the disrupted cell suspension of the  Monilia albicans.    
     
     
         4 . The pharmaceutical composition as set forth in  claim 1 ,  2 , or  3 , wherein the pharmaceutical composition is used for treating canine distemper.  
     
     
         5 . The pharmaceutical composition as set forth in  claim 1 ,  2 , or  3 , wherein the pharmaceutical composition is used for treating cerebral apoplexy, brain injury, neurological dysfunctions, Alzheimer's disease and myoclonus.  
     
     
         6 . A method of treating an animal infected with a canine distemper virus, comprising: 
 subcutaneously administering to the animal a pharmaceutical composition comprising a disrupted cell suspension of  Monilia albicans  and euglobulin as effective ingredients once to three times daily in a dose of 0.3 ml/kg to 2 ml/kg.    
     
     
         7 . The method as set forth in  claim 6 , wherein the euglobulin is contained in the pharmaceutical composition in an amount of 10 mg to 250 mg per ml of the disrupted cell suspension of the  Monilia albicans.    
     
     
         8 . The method as set forth in  claim 6  or  7 , wherein the pharmaceutical composition is administered in combination with a stomach protectant in a dose of 0.2 ml/kg to 0.3 ml/kg and an antibiotic in a dose of 0.3 ml/kg to 0.45 ml/kg once or twice daily.  
     
     
         9 . The method as set forth in  claim 8 , wherein the stomach protectant is selected from among metoclopramide hydrochloride, cimetidine and nuxvomica, and the antibiotic is selected from among sulfa drugs, cepha drugs, enrofloxacin, penicillin and ampicillin.  
     
     
         10 . A method of treating an animal with a neurological disorders such as cerebral apoplexy, brain injury, neurological dysfunctions, Alzheimer's disease or myoclonus, comprising: 
 subcutaneously administering to the animal a pharmaceutical composition comprising a disrupted cell suspension of  Monilia albicans  and euglobulin as effective ingredients once daily in a dose of 0.3 ml/kg to 0.6 ml/kg.    
     
     
         11 . The method as set forth in  claim 10 , wherein the euglobulin is contained in the pharmaceutical composition in an amount of 10 mg to 250 mg per ml of the disrupted cell suspension of the  Monilia albicans.    
     
     
         12 . The method as set forth in  claim 10  or  11 , wherein the pharmaceutical composition is administered in combination with a stomach protectant in a dose of 0.2 ml/kg to 0.3 ml/kg and an antibiotic in a dose of 0.3 ml/kg to 0.45 ml/kg once or twice daily.  
     
     
         13 . The method as set forth in  claim 12 , wherein the stomach protectant is selected from among metoclopramide hydrochloride, cimetidine and nuxvomica, and the antibiotic is selected from among sulfa drugs, cepha drugs, enrofloxacin, penicillin and ampicillin.